The stock of Opko Health Inc. (NASDAQ:OPK) is a huge mover today! About 3.03M shares traded hands. Opko Health Inc. (NASDAQ:OPK) has risen 7.53% since March 4, 2016 and is uptrending. It has underperformed by 0.51% the S&P500.
The move comes after 6 months negative chart setup for the $5.26B company. It was reported on Oct, 7 by Barchart.com. We have $9.26 PT which if reached, will make NASDAQ:OPK worth $315.60 million less.
Analysts await Opko Health Inc. (NASDAQ:OPK) to report earnings on November, 14. They expect $-0.03 EPS, down 112.00% or $0.28 from last year’s $0.25 per share. After $0.02 actual EPS reported by Opko Health Inc. for the previous quarter, Wall Street now forecasts -250.00% negative EPS growth.
According to Zacks Investment Research, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.”
Insitutional Activity: The institutional sentiment increased to 1 in Q2 2016. Its up 0.16, from 0.84 in 2016Q1. The ratio improved, as 33 funds sold all Opko Health Inc. shares owned while 63 reduced positions. 22 funds bought stakes while 74 increased positions. They now own 102.34 million shares or 2.14% more from 100.19 million shares in 2016Q1.
Commonwealth Equity Service last reported 66,958 shares in the company. Moreover, Qs Lc has 0% invested in Opko Health Inc. (NASDAQ:OPK) for 34 shares. Moreover, Kcg Inc has 0.04% invested in Opko Health Inc. (NASDAQ:OPK) for 218,087 shares. Century Cos Incorporated accumulated 42,764 shares or 0% of the stock. Capstone Invest Advsrs Lc accumulated 0.01% or 52,966 shares. California Public Employees Retirement Sys last reported 893,056 shares in the company. First Citizens Retail Bank Tru holds 0.01% or 11,000 shares in its portfolio. Dimensional Fund Advsr Lp holds 1.48M shares or 0.01% of its portfolio. Awm Investment Inc reported 350,000 shares or 0.7% of all its holdings. Central Commercial Bank & holds 500 shares or 0% of its portfolio. Gsa Capital Prns Llp holds 0.01% or 18,800 shares in its portfolio. Schwab Charles Invest Mgmt Incorporated has invested 0.01% of its portfolio in Opko Health Inc. (NASDAQ:OPK). Principal Gp Incorporated accumulated 64,988 shares or 0% of the stock. Benjamin F Edwards Communications Incorporated last reported 1,250 shares in the company. Gp One Trading L P last reported 734,019 shares in the company.
Insider Transactions: Since April 15, 2016, the stock had 53 insider purchases, and 0 selling transactions for $5.90 million net activity. Shares for $121,926 were bought by FROST PHILLIP MD ET AL on Monday, May 2.
More news for Opko Health Inc. (NASDAQ:OPK) were recently published by: Fool.com, which released: “Why Opko Health Shares Rallied 14% in September” on October 06, 2016. Fool.com‘s article titled: “Opko Health Has Big News on Deck” and published on September 27, 2016 is yet another important article.
OPK Company Profile
OPKO Health, Inc. (OPKO), incorporated on November 18, 1991, is a healthcare company. The Firm operates through two divisions: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The Company’s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism (SHPT) in patients with stage III or IV chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. The Company’s pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. The Firm has a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding firm in Ireland. It also owns a specialty active pharmaceutical ingredients (APIs) maker in Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.